Aijun Wang

Stem Cell Biology and Engineering, Extracellular Vesicle, Extracellular Matrix, Birth Defect, Gene Editing, Single Cell Spatial Multi-omics, IND enabling Studies and Clinical Trials

Dr. Wang's research focuses on developing tools and technologies, and therapeutics that integrate molecular, cellular, tissue and biomaterial engineering to promote regeneration and restore function. The Wang Group combines single cell spatial multi-omics (transcriptomics, proteomics, lipidomics, and metabolomics) with advanced bioengineering to investigate disease mechanisms and developmental biology. The team engineers stem cell-based therapies, non-viral gene editing platforms, extracellular vesicle and lipid nanoparticle (LNP) based nanotheranostics, as well as extracellular matrix and biomaterial scaffolds to address a broad spectrum of congenital conditions and acquired diseases. Dr. Wang specializes in advancing these therapeutic strategies from bench to bedside- leading efforts in discovery science, translational and IND-enabling studies, cGMP manufacturing, and clinical trials in both companion animal and human patients.